Kornimate/medical-research-clean huggingface dataset:
personalized mobile health platform to promote physical activity in adolescents and young adults with cystic fibrosis

Conditions: Cystic Fibrosis (CF)

Summary: the goal of this clinical trial is to help adolescents and young adults between the ages of 13-25 with cystic fibrosis (cf), medically stable, able to speak and read english, and are not experiencing a cf - related exacerbation, who are already active to remain, or gradually encourage them to increase their levels of physical activity participants will be asked to utilize a smartphone program, called nudge that we have developed. nudge is a chatbot with evidence-based features known to help teens make progress toward health goal: * set and review goals * self-monitor progress * provide feedback on goal attainment * revise future goals

the goal of this study is to conduct a 6-month delayed treatment pilot trial with adolescents and young adults (aya) ages 13-25 with cystic fibrosis (cf) or a cf related disorder) to establish feasibility and obtain data necessary to inform a phase iii efficacy trial. ayas 18 years-old and caregivers of ayas 13-17 years-old will complete the informed consent process. ayas 13-17 years-old will be asked to assent to participate in the study. after completion of the baseline study measures and return of actigraphy monitors, staff will notify ayas of their randomized assignment. ayas receiving nudge will then begin receiving intervention content for 6 months. ayas randomized to control will receive nudge at the conclusion of the month 3 study visit. study visits will occur at months 0, 3, and 6 with staff masked to treatment assignment.

Eligibility criteria:
inclusion criteria: 1. 13-25 years old 2. has a verified cf diagnosis or cf-related disorder 3. medically stable (i.e., fev1\&gt;30%, not experiencing a cf-related exacerbation) 4. speaks and reads english exclusion criteria: 1. have a comorbidity limiting pa participation (e.g., neurological condition) 2. have a significant cognitive impairment that interferes with study completion 3. have any oxygen, cpap or bipap requirement

Keywords: physical activity
mechano-chemical ablation versus compression

Conditions: Varicose Veins; Surgery

Summary: this study will be looking at the effect of endovenous mechano-chemical ablation (moca) in addition to multilayer elastic compression bandaging vs multilayer elastic compression bandaging only in patients with incompetent great saphenous vein (gsv) and venous ulcers (vu's).

the most severe form of chronic venous disease is venous ulceration with an overall prevalence of about 1% in the adult population. venous ulcers significantly impair quality of life, and their treatment places a heavy financial burden upon healthcare systems. to get the ulcer to heal, the current best treatment is to wear a compression bandage with multiple layers, with which about 60% of these ulcers will heal within 6 months. there is evidence that treatment of the varicose veins by sahenous veins stripping will prevent the ulcer recurrence. recent studies have suggested that novel proceduress of superficial truncal reflux elimination, such as foam sclerotherapy or treating the saphenous veins with termal (laser or radiofrequency) ablation to seal it effectively, may help the ulcers to heal more quickly and increase recurrence-free rate. these techniques can be carried out in the outpatient setting and are much better tolerated by patients in comparison to surgery. at the same time, no studies which compared compression plus endovenous mechanochemical ablation (moca) vs. compression alone in chronic venous ulcers have been conducted to date. the aim of this study is to see whether treatment of varicose veins using moca helps with healing.

Eligibility criteria:
inclusion criteria: 1. patient age \> 18 years. 2. current leg ulceration of greater than 6 weeks. 3. great saphenous vein (gsv) incompetence with reflux at least down to the knee level. 4. primary symptomatic varicose veins, clinical etiological anatomical pathophysiological (ceap) classification, clinical class c6. 5. able to give informed consent to participate in the study after reading the patient information documentation. 6. ankle brachial pressure index (abpi) ≥ 0.8. exclusion criteria: 1. postoperative varicose veins disease recurrence. 2. patients who are unable to tolerate any multilayer compression bandaging / stockings will be excluded. 3. deep venous thrombosis, thrombophilia associated with a high risk of deep venous thrombosis or postthrombotic syndrome. 4. history of pulmonary embolism or stroke. 5. current anticoagulation therapy (within 7 days of enrollment). 6. pregnant or lactating women.

Keywords: vv moca gsv venous ulcers
testing radon com methods: clinical trial smartphone app vs print brochures

Conditions: Lung Cancer

Summary: the purpose of this research study is to compare the effectiveness of radon information delivered via the radon app vs. a traditional approach (printed brochure). the prevalence of exceptionally high levels of residential radon in nd, coupled with public's poor understanding of this hazard, is a critical public health problem.


Eligibility criteria:
inclusion criteria: * the principal eligibility criterion is that participants own a smartphone. exclusion criteria: * the principal exclusion criterion is previous testing for radon within the past two years.
a clinical trial to evaluate the efficacy of an oral supplement in supporting vision and eye health

Conditions: Inflammation Symptoms; Eye Dryness; Eye Health

Summary: this study aims to evaluate the efficacy of bionaturehealth's eye empower supplement in supporting vision and eye health. it is a virtual, single-group trial lasting 3 weeks. participants will take three capsules of the supplement daily and complete questionnaires at baseline, week 1, week 2, and week 3 to assess visual clarity, dryness, symptoms of inflammation, and sensitivity to blue light.


Eligibility criteria:
inclusion criteria: * male or female at birth, aged 40 or over * self-reported concerns about at least two of the following symptoms: dry eyes, red/itchy/irritated eyes, sensitivity to blue light, blurred vision (far or near) * generally healthy without uncontrolled chronic diseases * willing to avoid using new eye health prescriptions, over-the-counter medications, supplements, and herbal remedies for the study duration * consistent use of current eye health supplements or herbal remedies for at least 3 months prior to the study * willing to maintain current diet, sleep schedule, and activity level during the study exclusion criteria: * pre-existing chronic conditions preventing protocol adherence, including oncological and psychiatric disorders * diagnosed diabetes (type i or ii) * planning to undergo any eye-related procedures during the study * recent surgeries or invasive treatments within the last six months * history of major illness within the last three months * recent use of a supplement with active ingredients in the test product * severe allergic reactions requiring an epipen, including shellfish allergy * pregnant, breastfeeding, or planning to conceive * use of medications or herbal supplements that impact the blood * non-consumption of animal products for religious or personal reasons * unwillingness to follow the study protocol * anyone with a history of drug or alcohol abuse

Keywords: vision health eye empower
the effects of tegaserod on mechanical sensitivity of the esophagus and stomach in patients with heartburn and dyspepsia.

Conditions: Heartburn; Dyspepsia

Summary: investigate the role of tegaserod in modulating gastric sensitivity to mechanical distention of the stomach


Eligibility criteria:
inclusion criteria: * male or female subjects at least 18 years of age. * subjects willing to undergo multiple nasogastric intubations. * patients with functional heartburn will need to meet rome ii criteria. * patients with symptoms consistent with dyspepsia (epigastric pain/discomfort characterized by bloating, postprandial fullness and early satiety) exclusion criteria: * subjects with clinically significant diarrhea or a diagnosis of diarrhea-predominant ibs. * subjects with a diagnosis of ibd, barrett's esophagus, esophageal stricture or ring, or previous or current history of ulcer disease. * subjects with diffuse esophageal spasm or achalasia. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: functional heartburn dyspepsia male female visceral sensitivity
lbh589 alone or in combination with erythropoietin stimulating agents (esa) in patients with low or int-1 risk myelodysplastic syndromes (mds)

Conditions: Myelodysplastic Syndrome (MDS)

Summary: this study assessed the efficacy and safety of lbh589 as single agent and in combination with esa in red blood cell transfusion-dependent low and int-1 mds patients being either refractory to esa or with a low probability of response. the study had a non-randomized core phase followed by a randomized phase.


Eligibility criteria:
key inclusion criteria: * patients with a lower risk mds (low or int-1 according to ipss) * red blood cell transfusion dependency of at least 4 units/8 weeks. * not responding to erythropoietin stimulating agents (esa) or having a low chance to do so * age-adjusted normal cardiac, kidney, liver function key exclusion criteria: * concomitant use of esa * concomitant use of any other investigational drug * other malignancy that is not in remission for at least 1 year * platelet count \< 75 x 109/l * impaired cardiac function or clinically significant cardiac diseases

Keywords: mds bone marrow anemia cytopenia transfusion dependance epo esa erythropoietin lbh589 myelodysplastic syndromes hematopoietic improvement ipss low ipss int-1 hi-e hdac inhibitor hdac-i dac-i deacetylase-inhibitor histone deacetylase-inhibitor red blood cell transfusions
serrated lesions detection with endocuff-assisted colonoscopy

Conditions: Serrated Lesion; Adenoma; Colorectal Cancer

Summary: colorectal cancer (crc) is a leading cause of morbidity and mortality worldwide, especially in western countries. crc is currently considered a preventable disease and screening has been endorsed by several societies, since it has been shown that screening and surveillance are effective in reducing both crc incidence and mortality. however, recently, concern has risen regarding colonoscopy effectiveness, especially in the right colon. the most accepted explanation for this effectiveness variability is attributed to sessile serrated lesions (ssl), which are more frequent in the proximal colon, more difficult to detect because of their flat morphology and associated with interval crc, which is the occurrence of crc after screening colonoscopy and before the next scheduled procedure. several techniques are emerging to increase the sensitivity of colonoscopy for pre-cancerous lesions, especially adenomas. recently an endoscopic cap, the endocuff, was developed to improve adenoma detection. several studies demonstrated improved adenoma detection with endocuff-assisted colonoscopy when compared with conventional colonoscopy. still, the available data for its' role in detecting ssl is very limited. the aim of this randomized controlled trial is to evaluate the effectiveness of endocuff-assisted colonoscopy in detection of colorectal ssl.


Eligibility criteria:
inclusion criteria: - outpatients undergoing elective colonoscopies exclusion criteria: * known polyposis syndromes * personal colorectal cancer history * previous colorectal surgery * severe diverticulosis * colonic stricture * inflammatory bowel disease * primary sclerosing cholangitis * pregnancy and breastfeeding

Keywords: serrated lesion endocuff detection
infant chest compression

Conditions: Cardiopulmonary Arrest

Summary: pediatric cardiac arrest is an uncommon but critical life-threatening event requiring effective cardiopulmonary resuscitation (cpr). about 16,000 pediatric cardiac arrests occurs in the united states annually. only 8% of the patients survive to hospital discharge and of these, up to two-thirds have neurological sequelae. majority of pediatric cardiac arrest are below age of two and have poorer chance of survival versus older children


Eligibility criteria:
inclusion criteria: * active paramedics * voluntary consent exclusion criteria: * pregnancy * back pain * wrist pain

Keywords: infant cardiopulmonary resuscitation hemodynamics chest compressions
the use of an online learning and consent platform in infertility treatment

Conditions: Patient Satisfaction

Summary: the primary purpose of this study is to objectively assess if interactive multimedia tutorials (online videos) enhances patients' comprehensive understanding of assisted reproductive technology (art) adding engagedmd, an online library of interactive videos, compared to the traditional process of consent and one-on-one teaching using a 15 question evaluation. the secondary outcome will be to qualitatively assess patients' overall experience of the teaching process comparing the addition of the engagedmd content to solely traditional teaching for infertility treatment.

participants: this will be a multi-center trial with each center planning on recruiting 100 couples. half of the couples will be planning on undergoing ovulation induction with insemination (oi/iui) and the other half in-vitro fertilization (ivf). procedures (methods): this is a multi-center prospective randomized controlled trial where couples undergoing oi/iui or ivf will be randomized to receiving the current traditional standard of in-person treatment teaching by their physician and nursing team with standard paper consents or to the identical process of in-person teaching with the addition of unrestricted access to the engagedmd online video resource platform with online consents. patient demographics, knowledge base, psychological impact of with the treatment, teaching and the consent process and overall satisfaction with the process as a whole will be assessed using surveys administered at three time points throughout the treatment process. a subset of patients that agree will be contacted after the completion of the treatment cycle for a live phone interview.

Eligibility criteria:
inclusion criteria: * female subjects must be 18-49 years of age undergoing fertility treatment * able to give informed consent exclusion criteria: * patients who do not have adequate command of the english language to provide informed consent

Keywords: patient education
a phase 1 study of duvelisib in patients with advanced hematologic malignancies

Conditions: Hematologic Malignancies

Summary: the purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of ipi-145 in patients with advanced hematologic malignancies.


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age; * progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease with no established therapy with the exception of expansion cohort of treatment naïve cll patients; * an eastern cooperative oncology group (ecog) score of 0 to 2. exclusion criteria: * any previous treatment with a pi3k inhibitor (escalation phase only) or within 4 weeks of the start of ipi-145 administration (expansion phase); * patients with overt leptomeningeal leukemia or cns lymphoma; * inadequate hepatic function defined by aspartate aminotransferase (ast) and/or alanine aminotransferase (alt) \> 2.5 x upper limit of normal (uln); direct bilirubin \>1.5 x uln; * inadequate renal function defined by serum creatinine \> 1.5 x uln

Keywords: phase 1
artemis: study of patients with early stage pancreatic cancer who have undergone genetic testing

Conditions: Pancreatic Adenocarcinoma; Pancreatic Cancer; Resectable Pancreatic Cancer

Summary: this study includes participants with pancreatic cancer who are undergoing genetic testing at invitae related to their diagnosis of pancreatic cancer. our goal in this study is two-fold. first, we would like to research whether any inherited changes in genes may be associated with pancreatic cancer. second, we would like to learn more about patient experiences with genetic testing, such as patient understanding of the testing, health-related actions taken (or planned to take) as a result of testing, communication and action of family members based on test results, and psychological impact of testing. this research study involves allowing collection of tumor tissue (from a prior biopsy and/or surgery), a blood sample, and sending surveys to participants for their opinion on the impact of the genetic testing as well as clinicians for relevant baseline and medical history information.

patients will be contacted for patient outcomes survey completion at months: 1, 4, 8, 12, 18, 24, 30, 36, 42, 48, 54, and 60. patients will also be contacted for survival collection every 6 months during years 3-5 post germline testing. clinicians will be contacted for relevant medical history, treatment, and survival data at the same time points. at baseline, 3 samples types will be collected: 1. edta tube for germline genetic testing. 2. streck tubes for whole genome sequencing and other analyses. 3. tumor block from surgical resection. if block is unavailable 10 unstained slides are an acceptable substitute.

Eligibility criteria:
inclusion criteria: * patient has consented to germline genetic testing * patient has a histologically confirmed diagnosis of pancreatic cancer * patient has undergone or is planned to undergo surgical resection with curative intent * patient is willing to allow collection of a tissue sample from surgical resection * patient is willing to provide research blood samples (every 6 months for 2 years) * patient must be at least 18 years of age exclusion criteria: * patient has evidence of metastatic or recurrent pancreatic cancer at time of consent * patient is unable to consent.

Keywords: germline genetic testing oncology pancreatic cancer resectable pancreatic cancer early stage pancreatic cancer
effects of early sensory reeducation programs using mirror therapy for patients with peripheral nerve injuries

Conditions: Sensation Disorders; Motor Deficit; Rehabilitation

Summary: this study evaluated the effects of an integrated program of touch-observation and task-based mirror therapy on sensorimotor function in nerve injury patients. before the return of protective sense (value of semmes-weinstein monofilament test \> 4.31), half of the participants received 15 minutes of mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy.while the other half received 15 minutes protective sensory reeducation programs, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session. once the patients had regained the protective sense (value of semmes-weinstein monofilament test \< 4.31), the discriminative sensory reeducation program was started for the participants in both groups. the hypothesis was that using the mirror therapy for sensorimotor reeducation in the early phase after nerve repair would yield better results with regard to the returning of sensation, sensorimotor control ability and hand function than using a classical reeducation program alone.


Eligibility criteria:
inclusion criteria: * median or ulnar nerve injury, * a combination of nerve and tendon or vascular injury, * injury sites between the level of mid-palm and elbow, and * the protective sensation of the hand is lacking or impaired. exclusion criteria: * patients with deficits in cognition or language comprehension, as well as severe limitations in the range of motion of the upper limbs.
safety and efficacy of intrathecal rituximab in 16 children of stage ⅲ、ⅳnon-hodgkin lymphoma

Conditions: Lymphoma, Non-Hodgkin; Child, Only

Summary: objective: this study demonstrated that the efficacy and safety of intrathecal(it) rituximab in the treatment of stage ⅲ and ⅳ non-hodgkin lymphoma(nhl) in children. methods: we reported 16 children were histologically diagnosed as stage ⅲ and ⅳ nhl from september 2015 to december 2020 who received it rituximab in pediatric oncology of sun yat-sen memorial hospital were restrospectively analyzed. the clinical manifestations, central nervous system involvement,treatment plan and prognosis of patients were analyzed.... all patients were pathologically positive for cd20 received the modified nhl-bfm 95, while it rituximab was arranged the day before the chemotherapy, which was simultaneously used with the intravenous infusion of rituximab. the median time of doses received by each patient was 5 times, every three weeks, with the it dose of 10 mg,15 mg, and 20 mg in increments.

malignant lymphoma is one of the most common malignancies in children, with approximately 60 percent of cases being b-cell, non-hodgkin lymphoma (nhl) . nhl in children progresses rapidly, prone to bone marrow and central nervous system (cns) involvement , cns-infested nhl has a poor prognosis regardless of primary or secondary , high-intensity chemotherapy, intravenous rituximab (rtx), radiotherapy, and hematopoietic stem cell transplantation, hsct) has limited efficacy in the treatment of these children because only a small percentage of drugs/antibodies can penetrate the blood-brain barrier . only a limited number of intrathecal agents, primarily methotrexate, steroids, and cytarabine, have been identified that have demonstrated safety in the use of cns-violated nhl but have not improved long-term survival in these children . therefore, whether safe and effective intrathecal drugs can be found is the focus of the treatment and prevention of cns-infused nhl. most b-cell nhl tumors express cd20 antigen in tumor tissues , rtx is a chimeric monoclonal antibody specific to b-cell cd20 antigen, and a large number of studies have confirmed that intravenous infusion of rtx has a good effect on adult and pediatric b-cell nhl . however, intravenous rtx concentrations in cerebrospinal fluid are low, ranging from 0.1 to 4.4 percent of the blood concentration, and repeated intravenous use does not increase its drug concentration in the cerebrospinal fluid . recent small clinical studies have shown that intrathecal rtx injection is safe in adult lymphoma patients , but there are no domestic cases of intrathecal rtx use in childhood lymphoma. in this paper, 16 clinical cases of intrathecal rtx injection of stage iii and iv. b-cell nhl were analyzed to explore the safety and efficacy of rtx intrathecal therapy.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of b lymphocyte nhl 2. age≤ 18 years old 3. normal heart and kidney function exclusion criteria: 1. heart, liver and kidney diseases 2. allergic to rituximab